Stacchiotti S. Frezza A.M. Blay J.Y. et al.

Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.

Cancer. 127: 2934-2942de Pinieux G. Karanian M. Le Loarer F. et al.

Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.

PLoS One. 16: e0246958Lau K. Massad M. Pollak C. et al.

Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer.

Chest. 140: 1312-1318Rosenbaum E. Jadeja B. Xu B. et al.

Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets.

Mod Pathol. 33: 591-602

Malignant vascular tumors--an update.

Mod Pathol. 27: S30-S38Stacchiotti S. Miah A.B. Frezza A.M. et al.

Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts.

ESMO Open. 6: 100170Shiba S. Imaoka H. Shioji K. et al.

Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study.

BMC Cancer. 18: 993Frezza A.M. Napolitano A. Miceli R. et al.

Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network.

ESMO Open. 6: 100083Rossi S. Orvieto E. Furlanetto A. et al.

Utility of the immunohistochemical detection of FLI-1 expression in round cell and vascular neoplasm using a monoclonal antibody.

Mod Pathol. 17: 547-552Righi A. Sbaraglia M. Gambarotti M. et al.

Primary vascular tumors of bone: a monoinstitutional morphologic and molecular analysis of 427 cases with emphasis on epithelioid variants.

Am J Surg Pathol. 44: 1192-1203Errani C. Zhang L. Sung Y.S. et al.

A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites.

Genes Chromosomes Cancer. 50: 644-653Suurmeijer A.J.H. Dickson B.C. Swanson D. et al.

Variant WWTR1 gene fusions in epithelioid hemangioendothelioma-a genetic subset associated with cardiac involvement.

Genes Chromosomes Cancer. 59: 389-395Kitaichi M. Nagai S. Nishimura K. et al.

Pulmonary epithelioid haemangioendothelioma in 21 patients, including three with partial spontaneous regression.

Eur Respir J. 12: 89-96Otrock Z.K. Al-Kutoubi A. Kattar M.M. et al.

Spontaneous complete regression of hepatic epithelioid haemangioendothelioma.

Lancet Oncol. 7: 439-441Shibayama T. Makise N. Motoi T. et al.

Clinicopathologic characterization of epithelioid hemangioendothelioma in a series of 62 cases: a proposal of risk stratification and identification of a synaptophysin-positive aggressive subset.

Am J Surg Pathol. 45: 616-626Bagan P. Hassan M. Le Pimpec Barthes F. et al.

Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma: a review of the literature.

Ann Thorac Surg. 82: 2010-2013Epelboym Y. Engelkemier D.R. Thomas-Chausse F. et al.

Imaging findings in epithelioid hemangioendothelioma.

Clin Imaging. 58: 59-65Sardaro A. Bardoscia L. Petruzzelli M.F. et al.

Epithelioid hemangioendothelioma: an overview and update on a rare vascular tumor.

Oncol Rev. 8: 259Tong D. Constantinidou A. Engelmann B. et al.

The role of local therapy in multi-focal epithelioid haemangioendothelioma.

Anticancer Res. 39: 4891-4896Yousaf N. Maruzzo M. Judson I. et al.

Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience.

Anticancer Res. 35: 473-480Frezza A.M. Ravi V. Lo Vullo S. et al.

Systemic therapies in advanced epithelioid haemangioendothelioma: a retrospective international case series from the World Sarcoma Network and a review of literature.

Cancer Med. 10: 2645-2659

Response of epithelioid haemangioendothelioma to liposomal doxorubicin.

Lancet Oncol. 6: 813-815Grenader T. Vernea F. Reinus C. et al.

Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin.

J Clin Oncol. 29: e722-e724Agulnik M. Yarber J.L. Okuno S.H. et al.

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.

Ann Oncol. 24: 257-263Chevreau C. Le Cesne A. Ray-Coquard I. et al.

Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).

Cancer. 119: 2639-2644Semenisty V. Naroditsky I. Keidar Z. et al.

Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.

BMC Cancer. 15: 402Kollar A. Jones R.L. Stacchiotti S. et al.

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.

Acta Oncol. 56: 88-92Stacchiotti S. Provenzano S. Dagrada G. et al.

Sirolimus in advanced epithelioid hemangioendothelioma: a retrospective case-series analysis from the Italian Rare Cancer Network database.

Ann Surg Oncol. 23: 2735-2744Schuetze S. Ballman K.V. Ganjoo K.N. et al.

P10015/SARC033: a phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).

J Clin Oncol. 39: 11503Gronchi A. Miah A.B. Dei Tos A.P. et al.

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up∗.

Ann Oncol. 32: 1348-1365Zimmermann C. Ryan S. Hannon B. et al.

Team-based outpatient early palliative care: a complex cancer intervention.

BMJ Support Palliat Care. https://doi.org/10.1136/bmjspcare-2019-001903Croteau S.E. Liang M.G. Kozakewich H.P. et al.

Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals.

J Pediatr. 162: 142-147Ji Y. Yang K. Peng S. et al.

Kaposiform haemangioendothelioma: clinical features, complications and risk factors for Kasabach-Merritt phenomenon.

Br J Dermatol. 179: 457-463Kasabach H.H. Merritt K.K.

Capillary hemangioma with extensive purpura: report of a case.

Am J Dis Child. 59: 1063-1070Lyons L.L. North P.E. Mac-Moune Lai F. et al.

Kaposiform hemangioendothelioma: a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma.

Am J Surg Pathol. 28: 559-568Drolet B.A. Trenor 3rd, C.C. Brandao L.R. et al.

Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma.

J Pediatr. 163: 285-291Ji Y. Chen S. Xiang B. et al.

Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective study.

Int J Cancer. 141: 848-855Hornick J.L. Fletcher C.D.

Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior.

Am J Surg Pathol. 35: 190-201Trombetta D. Magnusson L. von Steyern F.V. et al.

Translocation t(7;19)(q22;q13)-a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma?.

Cancer Genet. 204: 211-215Agaram N.P. Zhang L. Cotzia P. et al.

Expanding the spectrum of genetic alterations in pseudomyogenic hemangioendothelioma with recurrent novel ACTB-FOSB gene fusions.

Am J Surg Pathol. 42: 1653-1661Bridge J.A. Sumegi J. Royce T. et al.

A novel CLTC-FOSB gene fusion in pseudomyogenic hemangioendothelioma of bone.

Genes Chromosomes Cancer. 60: 38-42Hakar M.H. White K. Hansford B.G. et al.

Novel EGFL7-FOSB fusion in pseudomyogenic haemangioendothelioma with widely metastatic disease.

Histopathology. 79: 888-891Murshed K.A. Torres-Mora J. ElSayed A.M. et al.

Pseudomyogenic hemangioendothelioma of bone with rare WWTR1-FOSB fusion gene: case report and literature review.

Clin Case Rep. 9: 1494-1499Sugita S. Hirano H. Kikuchi N. et al.

Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics.

Diagn Pathol. 11: 75Hung Y.P. Fletcher C.D. Hornick J.L.

FOSB is a useful diagnostic marker for pseudomyogenic hemangioendothelioma.

Am J Surg Pathol. 41: 596-606Joseph J. Wang W.L. Patnana M. et al.

Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma.

Clin Sarcoma Res. 5: 22Ozeki M. Nozawa A. Kanda K. et al.

Everolimus for treatment of pseudomyogenic hemangioendothelioma.

J Pediatr Hematol Oncol. 39: e328-e331van I.D.G.P. Sleijfer S. Gelderblom H. et al.

Telatinib is an effective targeted therapy for pseudomyogenic hemangioendothelioma.

Clin Cancer Res. 24: 2678-2687Calonje E. Fletcher C.D. Wilson-Jones E. et al.

Retiform hemangioendothelioma. A distinctive form of low-grade angiosarcoma delineated in a series of 15 cases.

Am J Surg Pathol. 18: 115-125

Vascular tumours in infants. Part II: vascular tumours of intermediate malignancy [corrected] and malignant tumours.

Br J Dermatol. 171: 474-484Hirsh A.Z. Yan W. Wei L. et al.

Unresectable retiform hemangioendothelioma treated with external beam radiation therapy and chemotherapy: a case report and review of the literature.

Sarcoma. 2010https://doi.org/10.1155/2010/75624690Nayler S.J. Rubin B.P. Calonje E. et al.

Composite hemangioendothelioma: a complex, low-grade vascular lesion mimicking angiosarcoma.

Am J Surg Pathol. 24: 352-361Shang Leen S.L. Fisher C. Thway K.

Composite hemangioendothelioma: clinical and histologic features of an enigmatic entity.

Adv Anat Pathol. 22: 254-259Perry K.D. Al-Lbraheemi A. Rubin B.P. et al.

Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant.

Mod Pathol. 30: 1512Antonescu C.R. Dickson B.C. Sung Y.S. et al.

Recurrent YAP1 and MAML2 gene rearrangements in retiform and composite hemangioendothelioma.

Am J Surg Pathol. 44: 1677-1684Khan J.A. Maki R.G. Ravi V.

Pathologic angiogenesis of malignant vascular sarcomas: implications for treatment.

J Clin Oncol. 36: 194-201

Cellular injury and cell proliferation in skin carcinogenesis by UV light.

Oncology. 31: 61-75Painter C.A. Jain E. Tomson B.N. et al.

The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.

Nat Med. 26: 181-187

Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma.

Cancer. 92: 172-180Pereira E.S. Moraes E.T. Siqueira D.M. et al.

Stewart Treves syndrome.

An Bras Dermatol. 90: 229-231Makk L. Creech J.L. Whelan Jr., J.G. et al.

Liver damage and angiosarcoma in vinyl chloride workers. A systematic detection program.

JAMA. 230: 64-68Centeno J.A. Mullick F.G. Martinez L. et al.

Pathology related to chronic arsenic exposure.

Environ Health Perspect. 110: 883-886Daneshmend T.K. Bradfield J.W.

Hepatic angiosarcoma associated with androgenic-anabolic steroids.

Lancet. 2: 1249Ploegmakers M.J. Pruszczynski M. De Rooy J. et al.

Angiosarcoma with malignant peripheral nerve sheath tumour developing in a patient with Klippel-Trenaunay-Weber syndrome.

Sarcoma. 9: 137-140Calvete O. Martinez P. Garcia-Pavia P. et al.

A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families.

Nat Commun. 6: 8383Shustef E. Kazlouskaya V. Prieto V.G. et al.

Cutaneous angiosarcoma: a current update.

J Clin Pathol. 70: 917-925

Vascular sarcomas.

Curr Oncol Rep. 15: 347-355Young R.J. Brown N.J. Reed M.W. et al.

Angiosarcoma.

Lancet Oncol. 11: 983-991

Cutaneous malignant vascular neoplasms.

Clin Lab Med. 37: 633-646Mery C.M. George S. Bertagnolli M.M. et al.

Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival.

Cancer. 115: 4055-4063Chaudhary P. Bhadana U. Singh R.A. et al.

Primary hepatic angiosarcoma.

Eur J Surg Oncol. 41: 1137-1143Look Hong N.J. Pandalai P.K. Hornick J.L. et al.

Cardiac angiosarcoma management and outcomes: 20-year single-institution experience.

Ann Surg Oncol. 19: 2707-2715Li R. Li M. Zhang L.F. et al.

Clinical characteristics and prognostic factors of primary splenic angiosarcoma: a retrospective clinical analysis from China.

Cell Physiol Biochem. 49: 1959-1969Meis-Kindblom J.M. Kindblom L.G.

Angiosarcoma of soft tissue: a study of 80 cases.

Am J Surg Pathol. 22: 683-697Verbeke S.L. Bertoni F. Bacchini P. et al.

Distinct histological features characterize primary angiosarcoma of bone.

Histopathology. 58: 254-264Miettinen M. Lindenmayer A.E. Chaubal A.

Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens--evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor.

Mod Pathol. 7: 82-90Sullivan H.C. Edgar M.A. Cohen C. et al.

The utility of ERG, CD31 and CD34 in the cytological diagnosis of angiosarcoma: an analysis of 25 cases.

J Clin Pathol. 68: 44-50Behjati S. Tarpey P.S. Sheldon H. et al.

Recurrent PTPRB and PLCG1 mutations in angiosarcoma.

Nat Genet. 46: 376-379Italiano A. Chen C.L. Thomas R. et al.

Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.

Cancer. 118: 5878-5887Naka N. Tomita Y. Nakanishi H. et al.

Mutations of p53 tumor-suppressor gene in angiosarcoma.

Int J Cancer. 71: 952-955Murali R. Chandramohan R. Moller I. et al.

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.

Oncotarget. 6: 36041-36052Huang S.C. Zhang L. Sung Y.S. et al.

Recurrent CIC gene abnormalities in angiosarcomas: a molecular study of 120 cases with concurrent investigation of PLCG1, KDR, MYC, and FLT4 gene alterations.

Am J Surg Pathol. 40: 645-655Fernandez A.P. Sun Y. Tubbs R.R. et al.

FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations.

J Cutan Pathol. 39: 234-242Manner J. Radlwimmer B. Hohenberger P. et al.

MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema.

Am J Pathol. 176: 34-39Mentzel T. Schildhaus H.U. Palmedo G. et al.

Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases.

Mod Pathol. 25: 75-85Shon W. Sukov W.R. Jenkins S.M. et al.

MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study.

Mod Pathol. 27: 509-515Requena C. Rubio L. Lavernia J. et al.

Immunohistochemical and fluorescence in situ hybridization analysis of MYC in a series of 17 cutaneous angiosarcomas: a single-center study.

Am J Dermatopathol. 40: 349-354Bishop A.J. Zheng J. Subramaniam A. et al.

High terminal hemorrhage risk from cardiac angiosarcoma brain metastases warrants frequent brain imaging and early intervention.

Int J Radiat Oncol Biol Phys. 111: e314Mark R.J. Poen J.C. Tran L.M. et al.

Angiosarcoma. A report of 67 patients and a review of the literature.

Cancer. 77: 2400-2406Chen T.W. Burns J. Jones R.L. et al.

Optimal clinical management and the molecular biology of angiosarcomas.

Cancers (Basel). 12https://doi.org/10.3390/cancers1211332191Constantinidou A. Sauve N. Stacchiotti S. et al.

Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study.

ESMO Open. 5https://doi.org/10.1136/esmoopen-2020-000787105Ravi V. Wagner M. Chen T.W.-W. et al.

A phase II study of oraxol in the treatment of unresectable cutaneous angiosarcoma.

J Clin Oncol. 38: 11517Guadagnolo B.A. Zagars G.K. Araujo D. et al.

Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp.

Head Neck. 33: 661-667Pawlik T.M. Paulino A.F. McGinn C.J. et al.

Cutaneous angiosarcoma of the scalp: a multidisciplinary approach.

Cancer. 98: 1716-1726Young R.J. Natukunda A. Litiere S. et al.

First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.

Eur J Cancer. 50: 3178-3186Italiano A. Cioffi A. Penel N. et al.

Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.

Cancer. 118: 3330-3336Fury M.G. Antonescu C.R. Van Zee K.J. et al.

A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy.

Cancer J. 11: 241-247Penel N. Bui B.N. Bay J.O. et al.

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

J Clin Oncol. 26: 5269-5274Ray-Coquard I.L. Domont J. Tresch-Bruneel E. et al.

Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial.

J Clin Oncol. 33: 2797-2802Stacchiotti S. Palassini E. Sanfilippo R. et al.

Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network.

Ann Oncol. 23: 501-508Ray-Coquard I. Italiano A. Bompas E. et al.

Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO).

Oncologist. 17: 260-266Maki R.G. D'Adamo D.R. Keohan M.L. et al.

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

J Clin Oncol. 27: 3133-3140Jones R.L. Ravi V. Brohl A.S. et al.

Results of the TAPPAS trial: an adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS).

Ann Oncol. 30: v683Jones R.L. Ratain M.J. O'Dwyer P.J. et al.

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.

Eur J Cancer. 120: 132-139Wagner M.J. Othus M. Patel S.P. et al.

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).

J Immunother Cancer. 9https://doi.org/10.1136/jitc-2021-002990109Florou V. Rosenberg A.E. Wieder E. et al.

Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.

J Immunother Cancer. 7: 213Albores-Saavedra J. Schwartz A.M. Henson D.E. et al.

Cutaneous angiosarcoma. Analysis of 434 cases from the Surveillance, Epidemiology, and End Results Program, 1973-2007.

Ann Diagn Pathol. 15: 93-97Shin J.Y. Roh S.G. Lee N.H. et al.

Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: systematic review and meta-analysis.

Head Neck. 39: 380-386Weidema M.E. Flucke U.E. van der Graaf W.T.A. et al.

Prognostic factors in a large nationwide cohort of histologically confirmed primary and secondary angiosarcomas.

Cancers (Basel). 11https://doi.org/10.3390/cancers11111780150Bui N. Kamat N. Ravi V. et al.

A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.

Rare Tumors. 10 ()Fata F. O'Reilly E. Ilson D. et al.

Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face.

Cancer. 86: 2034-2037Apice G. Pizzolorusso A. Di Maio M. et al.

Confirmed activity and tolerability of weekly paclitaxel in the treatment of advanced angiosarcoma.

Sarcoma. 2016: 6862090Nagano T. Yamada Y. Ikeda T. et al.

Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients.

Cancer. 110: 648-651Dickson M.A. D'Adamo D.R. Keohan M.L. et al.

Phase II trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma.

Sarcoma. 2015: 532478Kim J.H. Park H.S. Heo S.J. et al.

Differences in the efficacies of pazopanib and gemcitabine/docetaxel as second-line treatments for metastatic soft tissue sarcoma.

Oncology. 96: 59-69Mehren M.V. Litwin S. Ravi V. et al.

Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS).

J Clin Oncol. 37: 11039

Kaposi. Idiopathisches multiples Pigmentsarkom der Haut.

Archiv für Dermatologie und Syphilis. 4: 265-273Chang Y. Cesarman E. Pessin M.S. et al.

Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Science. 266: 1865-1869Flore O. Rafii S. Ely S. et al.

Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus.

Nature. 394: 588-592Cesarman E. Damania B. Krown S.E. et al.

Kaposi sarcoma.

Nat Rev Dis Primers. 5: 9Iscovich J. Boffetta P. Franceschi S. et al.

Classic Kaposi sarcoma: epidemiology and risk factors.

Cancer. 88: 500-517Cook-Mozaffari P. Newton R. Beral V. et al.

The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic.

Br J Cancer. 78